To amend title V of the Federal Food, Drug, and Cosmetic Act to provide for extensions of marketing exclusivity periods for drugs in certain combinations of such drugs, and for other purposes.
The bill’s titles are written by its sponsor.
Sep 21, 2012
112th Congress, 2011–2013
Died in a previous Congress
This bill was introduced on September 21, 2012, in a previous session of Congress, but was not enacted.
Representative for California's 50th congressional district
Read Text »
Last Updated: Sep 21, 2012
Length: 13 pages
This is the first step in the legislative process.
H.R. 6502 (112th) was a bill in the United States Congress.
A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.
This bill was introduced in the 112th Congress, which met from Jan 5, 2011 to Jan 3, 2013. Legislation not enacted by the end of a Congress is cleared from the books.
How to cite this information.
We recommend the following MLA-formatted citation when using the information you see here in academic work:
Civic Impulse. (2017). H.R. 6502 — 112th Congress: Life-Threatening Diseases Compassion through Combination Therapy Act of 2012. Retrieved from https://www.govtrack.us/congress/bills/112/hr6502
“H.R. 6502 — 112th Congress: Life-Threatening Diseases Compassion through Combination Therapy Act of 2012.” www.GovTrack.us. 2012. April 23, 2017 <https://www.govtrack.us/congress/bills/112/hr6502>
|title=H.R. 6502 (112th)
|accessdate=April 23, 2017
|author=112th Congress (2012)
|date=September 21, 2012
|quote=Life-Threatening Diseases Compassion through Combination Therapy Act of 2012
Where is this information from?
GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.